Among patients with decompensated cirrhosis, the 30-day readmission rate was 20.7%, and predictors of readmission included education level, hepatic encephalopathy, elevated ALT, and Medicare.
Observational (n=222)
What are the predictors of hospital readmission in decompensated cirrhotic patients?
Readmissions are common in decompensated cirrhotics, with risk extending beyond 30 days and driven by factors like education, encephalopathy, ALT, and insurance type.
AIM: To reduce readmissions and improve patient outcomes in cirrhotic patients through better understanding of readmission predictors. METHODS: = 222). Primary outcomes were time to first readmission and 30-d readmission rate due to complications of cirrhosis. Clinical and demographic data were collected to help describe predictors of readmission, along with care coordination measures such as post-discharge status and outpatient follow-up. Univariate and multivariate analyses were performed to describe variables associated with readmission. RESULTS: One hundred thirty-two patients (59.4%) were readmitted at least once during the study period. Median time to first and second readmissions were 54 and 93 d, respectively. Thirty and 90-d readmission rates were 20.7 and 30.1 percent, respectively. Predictors of 30-d readmission included education level, hepatic encephalopathy at index, ALT more than upper normal limit and Medicare coverage. There were no statistically significant differences in readmission rates when stratified by discharge disposition, outpatient follow-up provider or time to first outpatient visit. CONCLUSION: Readmissions are challenging aspect of care for cirrhotic patients and risk continues beyond 30 d. More initiatives are needed to develop enhanced, longitudinal post-discharge systems.
Seraj et al. (Thu,) conducted a observational in Decompensated cirrhosis (n=222). Among patients with decompensated cirrhosis, the 30-day readmission rate was 20.7%, and predictors of readmission included education level, hepatic encephalopathy, elevated ALT, and Medicare.